{"url":"https://lda.senate.gov/api/v1/filings/4bb67457-6d4e-4e4d-8dd7-8d43064d33eb/","filing_uuid":"4bb67457-6d4e-4e4d-8dd7-8d43064d33eb","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2023,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/4bb67457-6d4e-4e4d-8dd7-8d43064d33eb/print/","filing_document_content_type":"text/html","income":null,"expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Burt Rosen","dt_posted":"2023-07-20T08:16:46-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"2501 Pennsylvania Ave. NW #3A","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20037","registrant":{"id":401105698,"url":"https://lda.senate.gov/api/v1/registrants/401105698/","house_registrant_id":null,"name":"BURT ROSEN STRATEGIES","description":"Government Affairs Strategies and Advice","address_1":"2501 Pennsylvania Ave. NW #3A","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20037","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"BURT ROSEN","contact_telephone":"+1 202-494-0437","dt_updated":"2025-05-21T11:43:11.385396-04:00"},"client":{"id":205958,"url":"https://lda.senate.gov/api/v1/clients/205958/","client_id":24,"name":"ATEA PHARMACEUTICALS","general_description":"Drug development and COVID 19 issues involving FDA, DOD, HHS, and OWS","client_government_entity":false,"client_self_select":null,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-06-12"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues specifically related to Covid drug development.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":73707,"prefix":null,"prefix_display":null,"first_name":"BURT","nickname":null,"middle_name":null,"last_name":"ROSEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}